Prostate Cancer Screening (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (09/29/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Description of the Evidence

Added text to state that Figure 1 shows the risk of prostate cancer death associated with prostate-specific antigen–based screening, compared with controls for up to 13 years of follow-up for each of the study centers in the European Randomized Study of Screening for Prostate Cancer (ERSPC) for which data are currently available; of the seven countries included in the study, only two countries reported a mortality benefit associated with prostate cancer screening, and it is not readily apparent which factors at these two sites might explain the observed difference.

Added Figure 1, Effects of Screening on Prostate Cancer Mortality.

Revised text to state that the Swedish (Goteborg) center for ERSPC reported results separately after the initial publication of the overarching ERSPC findings; the Goteborg center randomized approximately 20,000 men born between 1930 and 1944, and data from participants born between 1930 and 1939 were used in the pooled ERSPC data.

This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Harms of Screening

Next section >
About This PDQ Summary